What is Denali Therapeutics Inc.'s gross unrealized gains?

Denali Therapeutics Inc. (DNLI) reported gross unrealized gains of $236K in Q1 2026.

How has Denali Therapeutics Inc.'s gross unrealized gains changed year-over-year?

Denali Therapeutics Inc.'s gross unrealized gains decreased by 90.3% year-over-year, from $2.42M to $236K.

What is the long-term trend for Denali Therapeutics Inc.'s gross unrealized gains?

Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s gross unrealized gains has grown at a 52.0% compound annual growth rate (CAGR), from $130K to $1.05M.

Denali Therapeutics Inc. DNLI Gross Unrealized Gains

Gross Unrealized Gains at other companies

Regeneron PharmaceuticalsREGN

——

BiogenBIIB

——

BridgeBio PharmaBBIO

——

Krystal Biotech, Inc.KRYS

——

BioMarin PharmaceuticalsBMRN

——

BioCryst PharmaceuticalsBCRX

——

Other financials

Income statement

See full

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

See full

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

See full

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

See full

Market cap$3.93B+54.2%

Profitability

See full

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

See full

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s gross unrealized gains.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Denali Therapeutics Inc.'s gross unrealized gains?: Denali Therapeutics Inc. (DNLI) reported gross unrealized gains of $236K in Q1 2026.
How has Denali Therapeutics Inc.'s gross unrealized gains changed year-over-year?: Denali Therapeutics Inc.'s gross unrealized gains decreased by 90.3% year-over-year, from $2.42M to $236K.
What is the long-term trend for Denali Therapeutics Inc.'s gross unrealized gains?: Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s gross unrealized gains has grown at a 52.0% compound annual growth rate (CAGR), from $130K to $1.05M.